TG Therapeutics (FRA:NKB2) Marketable Securities: €62.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NKB2 TG Therapeutics Inc FRA:NKB2
80 GF Score
Price €48.20
GF Value €49.57
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics Marketable Securities?

TG Therapeutics FRA:NKB2 +5.93% 80 Marketable Securities is €62.5 Mil as of Mar. 2026. GuruFocus rates FRA:NKB2 with a GF Score™ of 80/100 and a GF Value™ of €49.57 (Fairly Valued). The stock has 8 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. TG Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was €62.5 Mil.

TG Therapeutics's annual Marketable Securities increased from Dec. 2023 (€114.2 Mil) to Dec. 2024 (€125.2 Mil) but then declined from Dec. 2024 (€125.2 Mil) to Dec. 2025 (€53.7 Mil).

TG Therapeutics  (FRA:NKB2) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

TG Therapeutics Marketable Securities Related Terms

TG Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Marketable Securities Chart

TG Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.05 56.05 114.24 125.21 53.65

TG Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.29 106.42 48.99 53.65 62.47
FRA:NKB2
80GF Score
TG Therapeutics Inc FRA:NKB2
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €62.5 Mil mean?
TG Therapeutics (FRA:NKB2) has a Marketable Securities of €62.5 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' Marketable Securities too high?
TG Therapeutics' current Marketable Securities is €62.5 Mil. Overall, TG Therapeutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Marketable Securities compare to PTGX and CRNX?
TG Therapeutics' Marketable Securities of €62.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Marketable Securities is €62.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €49.57, compared to a current price of €48.20 — trading 2.8% below its estimated fair value. The current Marketable Securities is €62.5 Mil. TG Therapeutics' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Marketable Securities is €62.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of €48.20 is trading 2.8% below its estimated GF Value™ of €49.57. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for FRA:NKB2:

  • Marketable Securities: €62.5 Mil
  • GF Value™: €49.57 vs. price of €48.20 (2.8% below fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges TGTX:USA1TGTX:Italy
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
80GF Score

Get the complete analysis for FRA:NKB2

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.20
Price
€49.57
GF Value